3.78

2.16% 0.08

Sab Biotherapeutics Inc (SABS)

Overview News Price History Financials Discussions Forecast

Sab Biotherapeutics Inc stock is traded at $3.78, with a volume of 176.37K. It is up +2.16% in the last 24 hours and up +6.78% over the past month. SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Previous Close:

$3.70

Open:

$3.7

24h Volume:

176.37K

Relative Volume:

0.26

Market Cap:

$343.93M

Revenue:

$114.70K

Net Income/Loss:

$-26.49M

P/E Ratio:

-1.5325

EPS:

-2.4665

Net Cash Flow:

$-53.17M

1W Performance:

+0.00%

1M Performance:

+6.78%

6M Performance:

-2.58%

1Y Performance:

+70.27%

1-Day Range:

$3.69

$3.85

1-Week Range:

$3.67

$3.85

52-Week Range:

$1.85

$5.15

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name

Sab Biotherapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

305-845-2813

Address

777 W 41ST ST, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

SABS's Discussions on Twitter

Compare SABS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SABS Sab Biotherapeutics Inc	3.78	336.65M	114.70K	-26.49M	-53.17M	-2.4665
VRTX Vertex Pharmaceuticals Inc	515.76	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.53	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.93	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-26	Initiated	Rodman & Renshaw	Buy
Dec-19-25	Initiated	Guggenheim	Buy
Sep-17-25	Initiated	Leerink Partners	Outperform
May-14-25	Resumed	H.C. Wainwright	Buy
Oct-09-24	Initiated	Craig Hallum	Buy
Aug-28-24	Initiated	Oppenheimer	Outperform
Nov-05-21	Initiated	Chardan Capital Markets	Buy

View All

Sab Biotherapeutics Inc Stock (SABS) Latest News

Aug 14, 2026

Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan

Aug 14, 2026

Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan

Aug 14, 2026

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan

Aug 14, 2026

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan

Aug 14, 2026

Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan

Aug 14, 2026

Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan

Aug 14, 2026

Aug 12, 2026

Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan

Aug 12, 2026

Aug 11, 2026

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 11, 2026